Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
13 hedge funds and large institutions have $147K invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 13 closing their positions.
48% less funds holding
Funds holding: 25 → 13 (-12)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
77% less capital invested
Capital invested by funds: $630K → $147K (-$483K)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VFA
Values First Advisors
Gray,
Tennessee
|
+$102K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$2.83K |
| 3 |
AA
Addison Advisors
Middlebury,
Vermont
|
+$34 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$226K |
| 2 |
Renaissance Technologies
New York
|
-$47.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$33K |
| 4 |
VF
Virtu Financial
New York
|
-$23K |
| 5 |
ACM
Aisling Capital Management
New York
|
-$16K |
NBRV Hedge Fund Activity: Q3 2022 in Review
13 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2022, worth a combined $147K — down 77% from $630K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NBRV and 1 opened new positions — a net loss of 12 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Values First Advisors, adding an estimated $102K. The largest seller was Fidelity Investments, cutting an estimated $226K.
- 13 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2022, down from 25 in Q2 2022.
- Funds reported $147K of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2022, down 77% quarter-over-quarter.
- 1 fund opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2022 and 13 closed out, a net change of -12 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2022 was Values First Advisors, an estimated $102K added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q3 2022 was Fidelity Investments, an estimated $226K sold.
Based on aggregated 13F filings for Q3 2022.